In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 74, Issue 1-4, 2012, Pages 201-210

  Mognetti, Barbara ^a   Barberis, Alessandro ^a   Marino, Silvia ^a   Berta, Giovanni ^a   De Francia, Silvia ^a   Trotta, Francesco ^a   Cavalli, Roberta ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Cyclodextrin; Anticancer agent; Drug delivery; Nanosponges; Paclitaxel

Indexed keywords

EID: 84864438172     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-011-0101-9     Document Type: Article

References (26)

1. H Gelderblom J Verweij K Nooter A Sparreboom 2001 Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 1590 1598 10.1016/S0959-8049(01)00171-X 1:CAS:528:DC%2BD3MXmt1Oqtb0%3D (Pubitemid 32778603)
2. MJ Hawkins P Soon-Shiong N Desai 2008 Protein nanoparticles as drug carriers in clinical medicine Adv. Drug Deliv. Rev. 60 876 885 10.1016/j.addr.2007.08.044 1:CAS:528:DC%2BD1cXlslagu7s%3D
3. AK Singla A Garg D Aggarwal 2002 Paclitaxel and its formulations Int. J. Pharm. 235 179 192 10.1016/S0378-5173(01)00986-3 1:CAS:528:DC%2BD38XhsV2qsro%3D (Pubitemid 34185449)
4. S Talegaonkar A Azeem FJ Ahmad RK Khar SA Pathan ZI Khan 2008 Microemulsions: a novel approach to enhanced drug delivery Recent Pat. Drug Deliv. Formul. 2 238 257 10.2174/187221108786241679 1:CAS:528:DC%2BD1cXhtlWnsr7O
5. A Sparreboom CD Scripture V Trieu PJ Williams T De A Yang B Beals WD Figg M Hawkins N Desai 2005 Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin. Cancer Res. 11 4136 4143 10.1158/1078-0432.CCR-04-2291 1:CAS:528:DC%2BD2MXks1Gks7g%3D (Pubitemid 40791578)
6. NK Ibrahim N Desai S Legha P Soon-Shiong RL Theriault E Rivera B Esmaeli SE Ring A Bedikian GN Hortobagyi JA Ellerhorst 2002 Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin. Cancer Res. 8 1038 1044 1:CAS:528:DC%2BD38XksVSqurg%3D (Pubitemid 34517637)
7. NK Ibrahim B Samuels R Page D Doval KM Patel SC Rao MK Nair P Bhar N Desai GN Hortobagyi 2005 Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer J. Clin. Oncol. 23 6019 6026 10.1200/JCO.2005.11.013 1:CAS:528:DC%2BD2MXhtVKgtb3I
8. C Li DF Yu RA Newman F Cabral LC Stephens N Hunter L Milas S Wallace 1998 Complete regression of well-established tumors using a novel water-soluble poly(l-glutamic acid)-paclitaxel conjugate Cancer Res. 58 2404 2409 1:CAS:528:DyaK1cXjs12qsrY%3D (Pubitemid 28252701)
9. CF Verschraegen K Skubitz A Daud AP Kudelka I Rabinowitz C Allievi A Eisenfeld JW Singer FB Oldham 2009 A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 63 903 910 1:CAS:528:DC%2BD1MXitlWhsLY%3D
10. P Sabbatini MW Sill D O'Malley L Adler AA Secord 2008 A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study Gynecol. Oncol. 111 455 460 10.1016/j.ygyno.2008.07.049 1:CAS:528:DC%2BD1cXhsVertbnK
11. M Mita A Mita J Sarantopoulos CH Takimoto EK Rowinsky O Romero P Angiuli C Allievi A Eisenfeld CF Verschraegen 2009 Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies. Cancer Chemother Pharmacol. 64 287 295 1:CAS:528:DC%2BD1MXms1ans74%3D
12. SD Chipman FB Oldham G Pezzoni JW Singe 2006 Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate Int. J. Nanomed. 1 375 383 10.2147/nano.2006.1.4.375 1:CAS:528:DC%2BD2sXjs1Witbw%3D
13. Szejtli, J.: Cyclodextrin technology, p. 450. Kluwer, Berlin (1988)
14. Trotta, F.; Tumiatti, W.: Patent WO 03/085002, 2003
15. F Trotta R Cavalli 2009 Characterization and application of new hyper-cross-linked cyclodextrins, Comp Interfaces 16 39 48 10.1163/ 156855408X379388 1:CAS:528:DC%2BD1MXksVWjsLo%3D
16. R Cavalli F Trotta W Tumiatti 2006 Cyclodextrin-based nanosponges for drug delivery J. Incl. Phenom. Macrocycl. Chem. 56 209 213 10.1007/s10847-006- 9085-2 1:CAS:528:DC%2BD28XhtFSitrfK
17. S Torne KA Ansari PD Vavia F Trotta R Cavalli 2010 Enhanced oral bioavailability after administration of paclitaxel-loaded nanosponges Drug Deliv. 17 419 425 10.3109/10717541003777233 1:CAS:528:DC%2BC3cXot1Wktro%3D
18. MP Hier MJ Black G Shenouda N Sadeghi SE Karp 1995 A murine model for the immunotherapy of head and neck squamous cell carcinoma Laryngoscope 105 1077 1080 10.1288/00005537-199510000-00013 1:STN:280:DyaK28%2FgvVCqsA%3D%3D
19. MS Alexander MM Kiser T Culley JR Kern JW Dolan JD McChesney J Zygmunt SJ Bannister 2003 Measurement of paclitaxel in biological matrices: high-throughput liquid chromatographic-tandem mass spectrometric quantification of paclitaxel and metabolites in human and dog plasma J. Chromatogr. B 785 253 261 10.1016/S1570-0232(02)00913-3 1:CAS:528:DC%2BD3sXmtVaksbY%3D (Pubitemid 36126165)
20. V Wagner A Dullart AK Bock A Zweck 2006 The emerging nanomedicine landscape Nat. Biotechnol. 24 1211 1217 10.1038/nbt1006-1211 1:CAS:528:DC%2BD28XhtVGgsrvI (Pubitemid 44564760)
21. H Hamada K Ishihara N Masuoka K Mikuni N Nakajima 2006 Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins J. Biosci. Bioeng. 102 369 371 10.1263/jbb.102.369 1:CAS:528:DC%2BD28Xhtlemsr3J (Pubitemid 44781320)
22. US Sharma SV Balasubramanian RM Straubinger 1995 Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins J. Pharm. Sci. 84 1223 1230 10.1002/jps.2600841015 1:CAS:528:DyaK2MXnvFSrtr4%3D
23. R Cavalli F Trotta ME Carlotti B Possetti M Trotta 2007 Nanoparticles derived from amphiphilic γ-cyclodextrins J. Incl. Phenom. Macrocycl. Chem. 57 657 661 10.1007/s10847-006-9269-9 1:CAS:528:DC%2BD2sXjs12ltr0%3D
24. E Bilensoy O Gurkaynak AL Dogan AA Hincal 2008 Safety and efficacy of amphiphilic β-cyclodextrin nanoparticles for paclitaxel delivery Int. J. Pharm. 347 163 170 10.1016/j.ijpharm.2007.06.051 1:CAS:528:DC%2BD2sXhtlOjsrnM (Pubitemid 350180328)
25. Y Liu GS Chen Y Chen DX Cao ZQ Ge YJ Yuan 2004 Inclusion complexes of paclitaxel and oligo(ethylenediamino) bridged bis (beta-cyclodextrin)s: solubilization and antitumor activity Bioorg. Med. Chem. 12 5765 5767
26. S Swaminathan L Pastero L Serpe F Trotta P Vavia D Aquilano M Trotta G Zara R Cavalli 2010 Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity Eur. J. Pharm. Biopharm. 74 193 201 10.1016/j.ejpb.2009.11.003 1:CAS:528:DC%2BC3cXhs1Oisbw%3D